It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The immortalized human ReNcell VM cell line represents a reproducible and easy-to-propagate cell culture system for studying the differentiation of neural progenitors. To better characterize the starting line and its subsequent differentiation, we assessed protein and phospho-protein levels and cell morphology over a 15-day period during which ReNcell progenitors differentiated into neurons, astrocytes and oligodendrocytes. Five of the resulting datasets measured protein levels or states of phosphorylation based on tandem-mass-tag (TMT) mass spectrometry and four datasets characterized cellular phenotypes using high-content microscopy. Proteomic analysis revealed reproducible changes in pathways responsible for cytoskeletal rearrangement, cell phase transitions, neuronal migration, glial differentiation, neurotrophic signalling and extracellular matrix regulation. Proteomic and imaging data revealed accelerated differentiation in cells treated with the poly-selective CDK and GSK3 inhibitor kenpaullone or the HMG-CoA reductase inhibitor mevastatin, both of which have previously been reported to promote neural differentiation. These data provide in-depth information on the ReNcell progenitor state and on neural differentiation in the presence and absence of drugs, setting the stage for functional studies.
Design Type(s) | cell differentiation design • proteomic profiling design • observation design • replicate design • factorial design |
Measurement Type(s) | proteomic profiling • cell differentiation |
Technology Type(s) | liquid chromatography-tandem mass spectrometry • fast live imaging |
Factor Type(s) | Stage • drug • passage number • biological replicate • technical replicate • primary antibody |
Sample Characteristic(s) | Homo sapiens • immortal cell line cell |
Machine-accessible metadata file describing the reported data (ISA-Tab format)
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Department of Systems Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
2 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
3 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Massachusetts General Hospital, Department of Neurology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
4 Laboratory of Systems Pharmacology, Program in Therapeutic Science, Harvard Medical School, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Department of Cell Biology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)